Dexamethasone implants appear to be the best treatment for persistent or recurrent macular edema that often occurs in patients with uveitis, findings from a new study show. The 12-week, multicenter, ...

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical ...

The 2003 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) was held in May in Fort Lauderdale, Florida. The retinal sessions were dominated by reports of new treatments ...

Pooling data from 317 published articles covering 690 individual patient cases, the review's authors searched PubMed, Scopus and the Cochrane Library for reports of noninfectious uveitis linked to a ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...

The treatment was approved in October 2021 and is the first FDA-approved therapy to treat macular edema associated with uveitis via injection to the suprachoroidal space, which provides a more ...

Intravitreal ceftazidime may help treat syphilitic uveitis when IV penicillin is delayed. Ceftazidime is not a substitute for IV penicillin, which is the preferred treatment. A case series reported ...

Please provide your email address to receive an email when new articles are posted on . Complex, multifactorial and associated with at least 40 different disorders, uveitis is the fifth leading cause ...

Please provide your email address to receive an email when new articles are posted on . Young ophthalmologists looking to specialize in retina and uveitis management can tailor their career to be as ...

Patients Treated in the Clinical Trial Exhibited Improvement in Best Corrected Visual Acuity No Meaningful Increases in IOP Observed; No Patient Required IOP-lowering Medication Clearside Biomedical, ...